Literature DB >> 1706098

Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients.

L Heikkilä1, R Rimón, L Terenius.   

Abstract

Radioimmunoassay procedures were used to assay levels of dynorphin A (DYN A) and substance P-like activity (SP) in cerebrospinal fluid (CSF) obtained from 10 schizophrenic patients before and after neuroleptic treatment, from 10 matched patients with other psychiatric disorders before and after treatment, and from 10 nonpsychiatric surgical controls. The highest mean concentration of CSF DYN A was found in the schizophrenic group on admission (significant vs. nonpsychiatric controls). The concentration remained almost unaltered after 4 weeks of zuclopenthixol treatment despite a highly significant decrease of overt psychopathology assessed by the Brief Psychiatric Rating Scale (BPRS). There was no significant difference between the mean CSF DYN A levels of the nonschizophrenic psychiatric patients and the surgical controls. When all psychiatric patients were pooled together, there was a significant correlation between the level of CSF DYN A and the BPRS total score. With regard to CSF SP levels, no statistically significant differences were observed within or between the groups studied. Neither was there a significant correlation between the concentration of CSF SP and overt psychopathology. Nevertheless, the mean CSF SP concentration of three patients with major depression was clearly higher than the corresponding mean concentration of the other patients in the nonschizophrenic group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706098     DOI: 10.1016/0165-1781(90)90001-l

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  11 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

Review 3.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Pain sensitivity is altered in animals after subchronic ketamine treatment.

Authors:  Axel Becker; Gisela Grecksch; Helmut Schröder
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

Review 6.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

7.  The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.

Authors:  Hugo A Tejeda; Vladimir I Chefer; Agustin Zapata; Toni S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

Review 8.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

9.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

10.  Effects of neonatal stress and morphine on kappa opioid receptor signaling.

Authors:  Thuy N Vien; Christine A Gleason; Sarah L Hays; Ronald J McPherson; Charles Chavkin; Sandra E Juul
Journal:  Neonatology       Date:  2009-05-27       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.